Prevalence of nasopharyngeal Streptococcus Pneumoniae carriage in infants: A systematic review and meta-analysis of cohort studies and randomized controlled trials DOI Creative Commons
Gulzhan N Beissegulova,

Б.А. Рамазанова,

Kamilya Mustafina

и другие.

PLoS ONE, Год журнала: 2024, Номер 19(12), С. e0315461 - e0315461

Опубликована: Дек. 18, 2024

This study aims to examine the prevalence of nasopharyngeal Streptococcus pneumoniae carriage (NSPC) in infants during their first two years life and compare rates among different vaccine groups country income-levels. will be achieved through a systematic review published literature, specifically focusing on data from cohort studies randomized controlled trials. A comprehensive search was conducted four electronic databases: PubMed, Web Science, ScienceDirect, Scopus, using predefined strategy. Forty-nine articles met inclusion criteria for this review. According results obtained random effects model, pooled mean NSPC 1.68% at birth (95% CI [0.50; 5.47]), 24.38% 1 4 months [19.06; 30.62]), 48.38% 6 [41.68; 55.13]), 59.14% 7 9 [50.88; 66.91]), 48.41% 10 12 [41.54; 55.35]), 42.00% 13 18 [37.01; 47.16]), 48.34% 19 24 [38.50; 58.31]). The highest were observed children aged across all groups. Low-income countries consistently demonstrated age categories studied. meta-analysis provide robust evidence high groups, with persistent regional disparities, especially low-income countries. highlights need continuous monitoring trends, particularly emergence non-vaccine serotypes. Policymakers healthcare providers should leverage these findings enhance vaccination strategies, aiming minimize overall burden pneumococcal diseases infants.

Язык: Английский

Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea DOI Creative Commons
Dong-Won Kang, Young June Choe, Ju‐Yeon Lee

и другие.

Vaccine, Год журнала: 2024, Номер 42(22), С. 126000 - 126000

Опубликована: Июнь 5, 2024

To evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to 13-valent (PCV13) for pediatric population in Korea, where four-dose coverage rate is over 97%.

Язык: Английский

Процитировано

6

Cost-Effectiveness Analysis of Pneumococcal Vaccine in the Pediatric Population: A Systematic Review DOI Open Access
Nam Xuan Vo,

Huong Lai Pham,

Uyen My Bui

и другие.

Опубликована: Авг. 12, 2024

Pneumococcal disease, caused by Streptococcus pneumoniae is the leading cause of high mortality in children worldwide. The tremendous direct cost hospital admissions and significant indirect costs from productivity loss contributed considerably to economic burden, with vaccination being only efficient way against illness. Our study aims summarize cost-effectiveness pneumococcal conjugate vaccine (PCV) implemented pediatric population. Employing online databases Pubmed, Embase, Medline, we looked for evaluation 2018 until March 2024. Incremental Cost-Effectiveness Ratios (ICER) Quality-Adjusted-Life-Years (QALY) were primary outcomes measuring PCV's cost-effectiveness. A 28-item CHEERS 2022 checklist was applied assess quality collected studies. Of 16 papers found, 9/16 discussed lower-valent (PCV13, PCV10) 7/16 examined higher-valent vaccine. (PCV20, PCV15). PCV13 PCV10 required more generated QALY compared no vaccination. Both PCV15 PCV20 averted substantial healthcare yielded greater life than PCV13. Additionally, a dominant strategy PCV15. Utilizing very cost-effective option not getting vaccinated. Transitioning would result higher gain cost-saving switching

Язык: Английский

Процитировано

3

Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review DOI Open Access
Nam Xuan Vo, Huong Pham,

Uyen My Bui

и другие.

Healthcare, Год журнала: 2024, Номер 12(19), С. 1950 - 1950

Опубликована: Сен. 29, 2024

Objectives: Pneumococcal disease, caused by Streptococcus pneumoniae, is the leading cause of mortality in children worldwide. The tremendous direct cost hospital admissions and significant indirect costs from productivity loss contribute considerably to its economic burden, with vaccination being only efficient protection against illness. Our study aims summarize cost-effectiveness pneumococcal conjugate vaccine (PCV) implemented pediatric population. Methods: Employing online databases PubMed, Embase, Medline, we looked for evaluations 2018 until March 2024. Incremental Cost-Effectiveness Ratios (ICER) Quality-Adjusted Life Years (QALY) were primary outcomes measuring PCVs. A 28-item CHEERS 2022 checklist was applied assess quality collected studies. Results: Of 16 papers found, 9/16 discussed lower-valent vaccines (PCV13, PCV10) 7/16 examined higher-valent (PCV20, PCV15). PCV13 PCV10 involved greater generated more QALY compared no vaccination. Both PCV15 PCV20 averted substantial healthcare yielded life than PCV13. Additionally, a dominant strategy PCV15. Conclusions: Utilizing very cost-effective option not getting vaccinated. Transitioning would result higher gain cost-saving switching

Язык: Английский

Процитировано

3

Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews DOI
Min Huang, Jipan Xie, Hela Romdhani

и другие.

PharmacoEconomics, Год журнала: 2025, Номер unknown

Опубликована: Май 23, 2025

Язык: Английский

Процитировано

0

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population DOI Creative Commons

C. Tzanetakos,

Ioanna Kokkinaki,

Myrto Barmpouni

и другие.

Expert Review of Vaccines, Год журнала: 2025, Номер unknown

Опубликована: Июнь 3, 2025

The aim of the present study was to evaluate cost-effectiveness 20-valent pneumococcal conjugate vaccine (PCV20) compared 13-valent (PCV13) and 15-valent (PCV15) for prevention disease in pediatric population Greece. A published decision-analytic Markov model adapted from payer perspective, compare PCV20 (under a 3 + 1 dosing schedule per EMA approval) with PCV13 PCV15 (both under 2 schedule) over 10-year time horizon. Inputs epidemiology, serotype coverage, effectiveness, utilities, direct medical costs (€2024) were sourced literature official data. Model outcomes included number invasive (IPD), noninvasive hospitalized pneumonia, non-hospitalized pneumonia otitis media (OM) cases, attributable deaths, costs, quality-adjusted life-years (QALYs) each vaccination strategy incremental ratios comparison. Scenario analyses assessed recent national recommendations. analysis indicated that, prevents an additional 1,953 1,514 cases IPD 54,956 42,069 343,353 271,864 OM 1,377 987 deaths respectively, resulting gain 23,065 (vs PCV13) 17,118 PCV15) QALYs respectively. lower PCV15, translated reduction total care cost €249 M vs €192 modeled showed that remained dominant schedule. Vaccination PCV20, whether or schedule, estimated be Greek infants, as expansion coverage morbidity costs.

Язык: Английский

Процитировано

0

Pediatric Otitis Media in the New Pneumococcal Conjugate Vaccines Era: What’s Next? DOI
Tal Marom, Sharon Ovnat Tamir

The Pediatric Infectious Disease Journal, Год журнала: 2024, Номер 43(6), С. 604 - 605

Опубликована: Март 19, 2024

*From the Department of Otolaryngology-Head and Neck Surgery, Samson Assuta Ashdod University Hospital, Ashdod, Israel †Faculty Health Sciences, Ben-Gurion Negev, Be'er-Sheva, Israel. Accepted for publication February 28, 2024 The authors have no funding or conflicts interest to disclose. Address correspondence: Tal Marom, M.D., Hospital Faculty 7, Harefu'ah street, 7747629, E-mail: [email protected], protected].

Язык: Английский

Процитировано

2

Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany DOI Creative Commons
Min Huang, Jessica Weaver, Elamin H. Elbasha

и другие.

Vaccines, Год журнала: 2024, Номер 12(9), С. 1045 - 1045

Опубликована: Сен. 12, 2024

This study aimed to evaluate the cost-effectiveness of routine childhood immunization with 20-valent pneumococcal conjugate vaccine (PCV20) in a four-dose regimen (3 + 1 schedule) versus 15-valent PCV (PCV15/V114) three-dose (2 1) Germany. The utilized decision-analytic Markov model estimate lifetime costs and effectiveness outcomes for single birth cohort tracked incidence acute infections long-term meningitis sequelae both vaccination strategies. data were derived from published clinical trials observational studies PCV7 PCV13. Indirect effects, such as herd protection serotype replacement, included model. adopted societal perspective, including direct medical, non-medical, indirect costs. Scenario sensitivity analyses performed. In base case, PCV20 prevented more disease cases deaths, an expected gain 96 quality-adjusted life years (QALYs) compared V114. However, was associated total incremental cost EUR 48,358,424, resulting ratio (ICER) 503,620/QALY. Most scenario estimated that ICER exceeded 150,000/QALY. Routine instead V114 may not be economically efficient use healthcare resources

Язык: Английский

Процитировано

1

The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US DOI Creative Commons

Aleksandar Ilic,

Maria J Tort, Alejandro Cané

и другие.

Vaccines, Год журнала: 2024, Номер 12(11), С. 1279 - 1279

Опубликована: Ноя. 14, 2024

(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses administered during the year of life at 2, 4, 6 months, while booster dose is given 12 to 15 months. This study evaluated health economic effects PCV20 infant series within compared PCV15. (2) Methods: Using decision-analytic model, we calculated introducing PCV15 or five subsequent birth cohorts. Epidemiological data were drawn from peer-reviewed studies estimates vaccine effectiveness extrapolated established PCV13 PCV7 efficacy studies. Direct medical costs related disease treatment extracted literature inflated 2024 dollars. (3) Results: Over course years, implementation vaccination newborns United States, PCV15, projected prevent an additional 220 cases invasive disease, 6542 community-acquired pneumonia, 112,095 otitis media across strategy could 66 deaths linked these illnesses confer extra gains, amounting 5058 years 5037 quality-adjusted years. These prevented estimated save approximately USD 147 million over 5 (4) Conclusions: demonstrated that vaccinating with months would yield substantially greater return due serotypes covered by PCV20.

Язык: Английский

Процитировано

0

Prevalence of nasopharyngeal Streptococcus Pneumoniae carriage in infants: A systematic review and meta-analysis of cohort studies and randomized controlled trials DOI Creative Commons
Gulzhan N Beissegulova,

Б.А. Рамазанова,

Kamilya Mustafina

и другие.

PLoS ONE, Год журнала: 2024, Номер 19(12), С. e0315461 - e0315461

Опубликована: Дек. 18, 2024

This study aims to examine the prevalence of nasopharyngeal Streptococcus pneumoniae carriage (NSPC) in infants during their first two years life and compare rates among different vaccine groups country income-levels. will be achieved through a systematic review published literature, specifically focusing on data from cohort studies randomized controlled trials. A comprehensive search was conducted four electronic databases: PubMed, Web Science, ScienceDirect, Scopus, using predefined strategy. Forty-nine articles met inclusion criteria for this review. According results obtained random effects model, pooled mean NSPC 1.68% at birth (95% CI [0.50; 5.47]), 24.38% 1 4 months [19.06; 30.62]), 48.38% 6 [41.68; 55.13]), 59.14% 7 9 [50.88; 66.91]), 48.41% 10 12 [41.54; 55.35]), 42.00% 13 18 [37.01; 47.16]), 48.34% 19 24 [38.50; 58.31]). The highest were observed children aged across all groups. Low-income countries consistently demonstrated age categories studied. meta-analysis provide robust evidence high groups, with persistent regional disparities, especially low-income countries. highlights need continuous monitoring trends, particularly emergence non-vaccine serotypes. Policymakers healthcare providers should leverage these findings enhance vaccination strategies, aiming minimize overall burden pneumococcal diseases infants.

Язык: Английский

Процитировано

0